Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.
  • Fireside chat with Mark Cuban at Access! 2023
    "You guys make such a huge difference that you don't get credit for."
    Mark Cuban on generic medicines.
  • Access! 2023 - AAM Annual Meeting
    ICYMI: See What Happened at Access! 2023
    Follow updates on social media with hashtag #Access2023.
  • AAM's Prescription for State Savings
    AAM’s Prescription for State Savings
    State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.
  • 2021 Savings for Patients by Condition
    Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. Learn more and download fact sheets about the savings by common patient conditions.
  • AAM 2022 U.S. Generic and Biosimilar Medicines Savings Report
    2022 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.
  • Study Finds Middlemen Increasingly Block Patient Access to New Generics
    New report shows that middlemen like health plans and pharmacy benefit managers (PBMs) increasingly block patient access, delaying coverage of new generics in favor of higher-priced brand drugs with high rebates.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Our Brands and Campaigns

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.